Our latest Investor Newsletter is out now.
Read the latest updates on progress towards our first in-human clinical trial of PAT-DX1, including a feature on why we’ve chosen to keep our clinical trial in Australia; a review of our deoxymab development activities; a closer look the deal landscape for DDR drugs; and a Q&A with Patrys’ new Chairman, Dr Charmaine Gittleson.